Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003805 · ClinicalTrials.gov registry record · Phase 3
Prevention of Infection in Patients With Hematologic Cancer and Persistent Fever Caused by a Low White Blood Cell Count
A Phase 3 study, sponsored by European Organisation for Research and Treatment of Cancer - EORTC.
- Completed
- Registry status
- Phase 3
- Development phase
- 859
- Enrollment target
NCT00003805 is a Phase 3 study that has completed, run by European Organisation for Research and Treatment of Cancer - EORTC. The registered enrollment target is 859 participants.
The verdict
NCT00003805, a Phase 3 study, has completed, sponsored by European Organisation for Research and Treatment of Cancer - EORTC.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 859 participants
- Enrollment target
Study Summary
RATIONALE: Antibiotic therapy may prevent the development of infection in patients with hematologic cancer and the persistent fever caused by a low white blood cell count. It is not yet known which regimen of antibiotics is most effective in preventing infection in these patients. PURPOSE: Randomized phase III trial to study the effectiveness of piperacillin-tazobactam with or without vancomycin in reducing fever in patients who have leukemia, lymphoma, or Hodgkin's disease.
Interventions
- DRUG vancomycin
- DRUG piperacillin sodium
- DRUG piperacillin-tazobactam
- DRUG tazobactam sodium
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 859 participants |
| Start Date | 1997-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00003805
The ClinicalTrials.gov registry entry for NCT00003805 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 859 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is European Organisation for Research and Treatment of Cancer - EORTC, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which vancomycin is the first listed.
NCT00003805 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00003805 about?
NCT00003805 is a clinical study titled "Prevention of Infection in Patients With Hematologic Cancer and Persistent Fever Caused by a Low White Blood Cell Count". RATIONALE: Antibiotic therapy may prevent the development of infection in patients with hematologic cancer and the persistent fever caused by a low white blood cell count. It is not yet known which regimen of antibiotics is most effective in preventing infection in these patients. PURPOSE: Randomiz...
What is the current status of trial NCT00003805?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 859 participants. The study started on 1997-11.
What interventions are being tested in trial NCT00003805?
The interventions under investigation include: vancomycin (DRUG), piperacillin sodium (DRUG), piperacillin-tazobactam (DRUG), tazobactam sodium (DRUG).
Who is sponsoring clinical trial NCT00003805?
This trial is sponsored by European Organisation for Research and Treatment of Cancer - EORTC, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.